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ABSTRACT
Phosphoinositide 3-kinase (PI3K) and Myc are known to cooperate in promoting 
the survival and growth of a variety of B-cell lymphomas. While currently there are 
no small molecule inhibitors of Myc protein, histone deacetylase (HDAC) inhibitors 
have been shown to reduce levels of Myc protein by suppressing its transcription. We 
assessed the efficacy of CUDC-907, a new rationally designed dual inhibitor of PI3K and 
HDACs, in a panel of lymphoma cell lines. CUDC-907 treatment resulted in a dose- and  
time-dependent growth inhibition and cell death of DLBCL cell lines, irrespective 
of the cell of origin. CUDC-907 treatment down-regulated the phosphorylation of 
PI3K downstream targets, including AKT, PRAS40, S6, and 4EBP1, increased histone 
3 acetylation, and decreased Myc protein levels. SILAC-based quantitative mass 
spectrometry demonstrated that CUDC-907 treatment decreased the protein levels of 
several components of the B cell receptor (BCR) and Toll like receptor (TLR) pathways, 
including BTK, SYK, and MyD88 proteins. These cellular changes were associated 
with an inhibition of NF-kB activation. CUDC-907 demonstrated in vivo efficacy with 
no significant toxicity in a human DLBCL xenograft mouse model. Collectively, these 
data provide a mechanistic rationale for evaluating CUDC-907 for the treatment of 
patients with Myc and PI3K-dependent lymphomas.
INTRODUCTION
There is clear evidence for the oncogenic cooperation 
between Myc and activated phosphoinositide 3-kinase 
(PI3K) signaling pathway in lymphomagenesis, providing 
an opportunity for developing mechanism-based therapy to 
disrupt this cooperative survival mechanism. Constitutive 
expression of AKT accelerated lymphomagenesis and 
resistance to chemotherapy in Eμ-Myc mouse model [1]. 
Similarly, combining constitutive c-Myc expression with 
constitutive PI3K activity in mouse germinal center B cells 
resulted in Burkitt lymphoma-like tumors [2]. Furthermore, 
analysis of primary human Burkitt lymphoma (BL) tissue 
sections revealed that two-thirds of the cases expressed 
high levels of phosphorylated AKT and S6 proteins, 
indicative of PI3K and mTORC1 activation [2]. 
Gene expression profiling has distinguished mainly 
two distinct molecular cell-of-origin subtypes: activated 
B cell-like (ABC) and germinal center B cell-like (GCB) 
[3, 4]. Constitutive activation of the NF-kB pathway 
is the hallmark of ABC DLBCL [5, 6], while the PI3K 
pathway promotes cell proliferation in GCB DLBCL [6]. 
Recently, genetic and proteomics studies have identified 
a prognostic role for Myc and Bcl2 genetic translocations 
and/or protein co-expression [7]. Most published series 
reported about 10% of DLBCL harbored Myc, Bcl2 and/or 
Bcl6 translocations and predominantly seen in the subset 
of GCB subtype [7–13]. This category was called “double 
hit” lymphoma (DHL) or triple hit lymphoma and now 
is recognized as “high grade B-cell lymphoma (HGBL) 
with rearrangements of Myc and Bcl2 and/or Bcl6 [14]. 
Prior attempts to develop small molecule inhibitors that 
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specifically and directly target c-Myc protein have been 
unsuccessful.  However, Myc cellular protein abundance 
can be decreased by using epigenetic modifying drugs 
(HDAC inhibitors or bromodomain/BET inhibitors) that 
are known to inhibit Myc transcription [15, 16].
In this study, we investigated the ability of CUDC-907, 
a new chemically-designed, oral small molecule that 
combines the active hydroxamate moiety of HDAC 
inhibitor with a PI3K inhibitor into a single scaffold [17]. 
We demonstrate that CUDC-907, as a single agent, is 
capable of disrupting the oncogenic cooperation between 
Myc and PI3K, providing a rationale for evaluating 
this novel compound in patients with Myc and PI3K-
dependent lymphomas.
RESULTS
In vitro activity of CUDC-907 in lymphoma cell lines
To assess the effect of CUDC-907 on cell 
proliferation, cells were incubated with increasing 
drug concentrations (from 0.01 to 10 µM) for 24, 48 
and 72 hours (hrs). CUDC-907 treatment resulted in 
growth inhibition in a dose and time dependent manner 
(Figure 1A) with an IC50 < 0.1 µM in 17 out 20 (82%) 
lymphoma cell lines at 72 hrs (Figure 1B) (Supplementary 
Table 1). CUDC-907 demonstrated activity in both ABC 
and GCB) [4] cell lines irrespective of genetic alterations, 
including the presence of dual translocation involving 
c-Myc and Bcl2 (DHL) (Figure 1B). Using Annexin 
V- propidium iodide staining, we found that CUDC-
907 induced cell death by apoptosis after 24 hrs at low 
concentration (0.1 µM) in three representative DLBCL 
cell lines, SUDHL-6 (GCB), HBL-1 (ABC) and NUDHL-1 
(DHL), but was ineffective in the Hodgkin lymphoma (HL) 
cell line KMH-2 (Figure 1C). Consistent with these data, 
the induction of apoptosis was associated with caspase 3 
and PARP cleavage in the sensitive DLBCL cell lines, but 
not in the HL cell line (Figure 1D).
CUDC-907 downregulates c-Myc and PI3K 
downstream targets
To investigate the mechanism of action of CUDC-907 
we first examined its effect on PI3K and HDAC targets. 
As expected, CUDC-907’s inhibition of HDAC resulted in 
an increase of acetylated histone 3, leading to a decrease 
of c-Myc protein levels (Figure 2A). Similarly, CUDC-907 
inhibited PI3K pathway activation, as indicated by the dose-
dependent decreases in phosphorylation of downstream 
targets (p4EBP1, pPRAS40 and pS6) in the sensitive B-cell 
lines (Figure 2A). Using a multiplex assay for pAKT (Thr 
308) we observed inhibition at 30 minutes. However, AKT 
phosphorylation progressively increased in most cells in 
time dependent manner (Supplementary Figure 1) likely 
due to the loss of the negative feedback loop between pS6 
and insulin receptor substrate 1 (IRS-1) [18].
Next, we investigated the molecular mechanism of 
each single agent using the HDAC inhibitor panobinostat 
and the PI3K inhibitor BKM-120, alone and in combination 
at their IC50 concentrations (Supplementary Table 2), 
and compared the results to single agent CUDC-907. 
As shown in Figure 2B and 2C, treatment with single 
agent CUDC-907 produced similar molecular effects on 
pS6, acetylated H3, and c-Myc levels compared with 
the combination of panobinostat and BKM-120. These 
molecular changes were associated with similar biologic 
antiproliferative activity in DLBCL cell lines (Figure 2D). 
Collectively, these data demonstrate that CUDC-907 
is indeed a dual inhibitor of PI3K and HDACs, with 
antiproliferative activity similar to the combination of 
BKM-120 and panobinostat.
Quantitative proteomics identifies novel targets 
of CUDC-907 in DLBCL
To identify additional downstream targets of 
CUDC-907, we performed a stable isotope labeling of 
amino acids in cell culture (SILAC)–based quantitative 
mass spectrometry. We applied this technique to two 
representative DLBCL cell lines treated with 0.1 μM 
CUDC-907 for 24 hrs (HBL-1 of ABC origin, and 
SUDHL-6 of GCB origin). Of the 5447 proteins 
detected in both HBL-1 and SUDHL-6 cells, 120 
proteins were commonly increased or decreased after 
treatment with CUDC-907 in both cell lines (Figure 3A 
and Supplementary Table 3). CUDC-907 consistently 
decreased the level of proteins involved in B cell receptor 
(BCR) and Toll like receptor (TLR) signaling (Figure 3B 
and Supplementary Figure 2B). These effects were 
confirmed in a wider range of DLBCL cell lines by western 
blots (Figure 3C). Because the gain-of-function mutation 
MyD88 L265P is well known to confer oncogenic 
properties in DLBCL [3, 19], we further examined the 
effect of CUDC-907 in cell lines that harbor this mutation. 
As shown in Figure 3D, CUDC-907 reduced MyD88 
protein level in all the mutant cell lines. Furthermore, the 
reduction in MyD88 protein level was associated with 
a rapid and profound decrease in MyD88 mRNA level 
irrespective of the mutation status (Figure 3E). The effect 
of CUDC-907 on MyD88 protein was predominantly 
driven by its HADC inhibitory property, as similar effect 
was observed by treating the cells with panobinostat, but 
not with the PI3K inhibitor BKM-120 (Figure 3F).
Given that BCR and TLR signaling leads to NF-kB 
activation (Supplementary Figure 2C), we investigated 
whether CUDC-907 treatment can also inhibit NF-kB. 
Therefore, we treated two representative ABC cell lines, 
which are characterized by aberrant activation of NF-kB 
[5, 6], with CUDC-907 for 12 hrs and determined its 
effect on NF-kB activity using a luciferase promoter 
assay containing NF-kB binding site motif. As shown in 
Figure 4A, CUDC-907 inhibited NF-kB activity in both 
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Figure 1: Antiproliferative activity of CUDC-907 in B-cell lymphoma cell lines. (A) MTS assay of 8 representative DLBCL 
and 2 Hodgkin lymphoma cell lines treated with increasing dose of CUDC-907 from 0.01 to 10 μM for 24, 48, 72 hours. Error bars represent 
standard error of the mean (S.E.M) of triplicate experiments. (B) Bar graph showing IC 50 values of CUDC-907 in B cell (n = 17) and 
Hodgkin lymphoma (n = 3) cell lines after treatment for 72 hours (upper panel). CUDC-907 demonstrated efficacy irrespective of the cell 
of origin, genetic alterations or mutations of histone modifiers genes, Myc and BCL-2 rearrangements. Viability was determined by MTS 
assay. Error bars represent S.E.M. of triplicate experiments. (C) CUDC-907 induces apoptosis in lymphoma cell lines. SUDHL-6, HBL-1, 
NUDHL-1 and KMH-2 cells were treated for 24 hours with CUDC-907 0.1 μM before they were stained with propidium iodide and annexin 
V and analyzed by flow cytometry (left panel). Bar graphs summarizing the results of 3 independent experiments in SUDHL-6, HBL-1, 
NUDHL-1 and KMH-2 cells. Each bar represent the percentage of dead cells shown in the right upper and lower quadrants (annexin 
positive cells). Error bars represent S.E.M. of triplicate experiments. Differences between groups were calculated with the Student's t test. 
*p < 0.05; **p < 0.005. (D) Representative western blot showing caspase 3 cleavage and PARP cleavage after 24 hours of incubation with 
0.1 μM CUDC-907 in SUDHL-6, HBL-1 and NUDHL-1 cells lines, but not in KMH-2 cells.
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Figure 2: CUDC-907 inhibits c-Myc and HDACs in DLBCL cell lines. (A) Western blot analysis demonstrating the effect of 
increasing concentration of CUDC-907 (from 0.01 to 1 μM) on PI3K downstream targets (p4EBP1, pPRAS40 and pS6) and histone H3 
acetylation (Ac Histone H3). The actual inhibition of PI3K and HDAC resulted in a decrease in c-Myc protein levels. Activation of caspase 
3 and PARP was present as well. (B) Western blot analysis showing the effect of single agent PI3K inhibitor (BKM-120), HDAC inhibitor 
(panobinostat), or both on PI3K and HDAC targets. The data show that CUDC-907 produces similar results to the combination of BKM-120 
and panobinostat. (C) CUDC-907 combines PI3K and HDAC inhibitor into a single scaffold, and therefore is capable of disrupting the 
oncogenic cooperation between PI3K and c-Myc. (D) MTS assay demonstrating that CUDC-907 inhibits cell proliferation, mimicking the 
effect of BKM-120 plus panobinostat. Cells were incubated with increasing concentrations of BKM-120, panobinostat and CUDC-907, 
and viability assessed after 24 hours.
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cell lines, an effect that was reproduces by panobinostat 
but not by BKM-120. CUDC-907 treatment was 
associated with up-regulation of inhibitor of kappa B 
alpha (IkBα) and down-regulation of inhibitor of NF-kB 
subunit beta (IKK beta) and IRF4 consistent with NF-kB 
pathway inhibition (Figure 4B and Supplementary 
Figure 3). CUDC-907 treatment (0.1 μM CUDC-907 for 
12 hours) resulted in a marked reduction in NF-kB nuclear 
activity, which was more pronounced in the ABC cell lines 
(HBL-1 and TMD-8) compared with the GCB cell lines 
(SUDHL-6 and SUDHL-4) (Figure 4C).
In vivo efficacy of CUDC-907 in DLBCL 
xenograft model
We next investigated the efficacy of CUDC-907 
in a xenograft model of GCB and ABC DLBCL. NOD.
Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice implanted 
Figure 3: Quantitative proteomics identifies B-cell receptor signaling proteins as targets for CUDC-907 in DLBCL 
cell lines. (A) Summary graph showing fold change cellular proteins that are commonly up or down-regulated in both HBL-1 (blue) and 
SUDHL-6 (red) cells. (B) A subset analysis of the experiments shown in Figure 3A, demonstrating the effect of CUDC-907 treatment 
(0.1 μM for 24 hours) on proteins involved in BCR and TLR signaling. Each value represents the average of the fold change (CUDC-907 
vs DMSO) obtained in the forward and the reverse experiments. (C) Western blot confirming the effect of CUDC-907 (0.1 μM for 24 hours) 
on BCR and TLR signaling proteins in B-cell lymphoma cell lines (GCB n = 3 and ABC n = 3). (D) Western blot demonstrating the effect 
of CUDC-907 (0.1 μM) on MyD88 protein in a panel of ABC DLBCL cells (HBL-1, TMD-8 and OCI-LY-10 harbor the MyD88 mutation 
L265P). (E) Change in relative mRNA levels of MyD88 over time in B-cell lymphoma cell line panel (GCB n = 3 and ABC = 4) after 
treatment with CUDC-907 0.1 μM for the indicated time. (F) Western blot demonstrating that CUDC-907 or panobinostat can decrease 
cellular abundance of MyD88 and BTK in DLBCL cell lines. The analysis was performed after 24 hours of incubation with each drug at 
the indicated concentration.
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subcutaneously with SUDHL-6 and TMD-8 cell-derived 
tumors were treated orally with either vehicle or CUDC-907 
at 25, 50 and 100 mg/kg, 5 times weekly [17]. CUDC-907 
produced a significant inhibition of DLBCL tumor growth 
in a dose-dependent manner. The most growth delay 
was observed at 100 mg/kg in both models (Figure 5A). 
Overall, CUDC-907 was well tolerated, as it did not 
induce a significant weight loss, or other clinical signs, 
in treated mice (Figure 5B). We evaluated also the 
in vivo activity of CUDC-907 on its molecular targets in 
harvested tumors by western blot. CUDC-907 therapy 
resulted in down-regulation of PI3K and NF-kB signaling 
pathways as indicated by decrease in pS6 and IRF4 24 
hrs post dosing (Figure 5C, 5D). Similarly, CUDC-907 
inhibited HDACs leading to an increase in histone H3 
acetylation and a decrease in c-Myc and MyD88 protein 
levels (Figure 5C, 5D). Relatively increased of PARP was 
also detected as marker of apoptosis (Figure 5C). 
DISCUSSION
Several previous studies demonstrated the oncogenic 
cooperation between Myc and PI3K signaling pathway in 
a variety of lymphomas [1, 2]. As HDAC inhibitors can 
inhibit Myc transcription [15, 16], several investigators 
attempted disrupting Myc and PI3K cooperation by 
combining HDAC inhibitors and PI3K pathway inhibitors 
[20, 21]. A synergic activity was demonstrated in DLBCL 
irrespective of subtype [20]. In this study, we demonstrate 
that CUDC-907, as a single agent, can reproduce the 
molecular and biologic activity of the two drugs in 
combination (HDAC inhibitor plus PI3K inhibitor). At the 
molecular level, CUDC-907 inhibited the phosphorylation 
of PI3K downstream targets, in addition to inhibition of 
HDACs, resulting in an increase in histone H3 acetylation 
and Myc down-regulation (Figure 2C). As a consequence, 
CUDC-907 induced caspase activation, PARP cleavage, 
Figure 4: CUDC-907 inhibits NF-kB signaling in ABC DLBCLs. (A) Relative NF-kB-luciferase activity in two representative 
ABC DLBCL cell lines (HBL-1 and TMD-8). Cells were treated for 12 hours with indicated concentration of either panobinostat, BKM-120, 
the combination of these two drugs, CUDC-907 or DMSO. Cells were incubated with 2 ng of TNF-α as positive control for NF-kB 
activation. Error bars represent standard error of the mean (S.E.M) of triplicate experiments. (B) Western blot demonstrating that CUDC-907 
(0.1 μM for 6 and 12 hours) inhibits NF-kB activation by increasing IkB alpha levels and decreasing IKK beta levels in two representative 
ABC DLBCL cell lines (HBL-1 and TMD-8). The changes were associated with a decrease in IRF4 levels (see Supplementary Figure 2B). 
(C) ELISA assay showing a more pronounced decrease of nuclear NF-kB p65 in two representative ABC (HBL-1 and TMD-8) cell lines 
compared with two GCB (SUDHL-6 and SUDHL-4) treated with either 0.1 μM CUDC-907 or DMSO for 12 hours. Differences between 
groups were calculated with the Student's t test. *p < 0.05; ***p < 0.001.
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Figure 5: CUDC-907 therapy in xenograft model of GCB and ABC DLBCL. (A) Human SUDHL-6 and TMD-8 DLBCL cells 
were established as s.c. tumors in NOD/SCID mice and treated orally with vehicle (n = 8) or CUDC-907 at 25 (n = 8), 50 (n = 8) and 100 
(n = 8) mg/kg, 5 times weekly. CUDC-907 inhibits tumor growth in a dose-dependent manner when compared with the control group. Tumor 
volume was measured 3 times per week. Differences between groups were calculated with the Student's t test. **p < 0.005; ***p = 0.0001; 
****p < 0.00001. (B) Variations of body weight over time in SUDHL-6 and TMD-8 xenografts treated with CUDC-907 at 25, 50 and 50 mg/kg. 
(C) In vivo effects of CUDC-907 on pS6, c-Myc, MyD88, IRF4, PARP and acetyl histone H3 levels in SUDHL-6 and TMD-8 xenografts 
after 24 hours from the last drug administration. Proteins were extracted from tumor tissues and analyzed by western immunoblotting to 
assess in vivo inhibition of indicated targets. (D) Scatterplots summarizing changes in expression levels of pS6, c-Myc, MyD88 and IRF4, 
expressed as ratios of pixel densities between actin and protein of interest. Densitometry was performed by using the ImageJ software. 
Differences between groups were calculated with the Wilcoxon Rank test. *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant. 
Oncotarget14024www.impactjournals.com/oncotarget
and cell death in different subtypes of DLBCL cell lines, 
but not in the less-sensitive Hodgkin lymphoma cells. 
Furthermore, CUDC-907 decreased the cellular abundance 
of key proteins involved in BCR and TLR signaling 
pathways, resulting in inhibition of NF-kB activation. 
The in vitro activity was confirmed in a human DLCBL 
xenograft model, whereas CUDC-907 was capable of 
inhibiting PI3K and HDACs in vivo. In a previous study 
CUDC-907 has been shown to be more effective than 
PI3Ki and HDACi in a B lymphoma mouse model [17]. 
We demonstrated that CUDC-907 induced growth 
inhibition of both GCB and ABC DLBCL subtypes. These 
findings indicate that CUDC-907 may have a role in the 
treatment of Myc-expressing DLBCL and ABC-DLBCL, 
which are known to have a poor outcome when treated 
with standard combination chemotherapy [22].
Our preclinical observations provided a rationale for 
evaluating CUDC-907 in patients with relapsed DLBCL, 
especially those with high Myc expression.  Results from 
a recently published phase-I study demonstrated the 
safety and clinical efficacy of CUDC-907 in patients with 
relapsed DLBCL [23]. A major advantage of combining 
HDAC and PI3K inhibitors in a single scaffold is the 
simplicity and ease of administration, likely resulting in 
improved patients compliance. Furthermore, combining 
both drugs in a single scaffold simplifies future 
combination strategies, especially with other novel small 
molecule inhibitors. However, because each CUDC-907 
molecule combines an HDAC inhibitor and a PI3K 
inhibitor in a 1:1 fixed ratio, it is not possible to adjust the 
dose of each component separately to improve treatment 
efficacy or to decrease drug-related toxicity.
The ability of CUDC-907 to modulate BCR and 
TLR signaling may indicate that the drug should be 
examined in combination with BCR signaling inhibitors, 
such as SYK or BTK inhibitors. Furthermore, because 
CUDC-907 down-regulated the expression of MyD88 
transcripts and protein, irrespective of its mutation status, 
future studies could focus on investigating a potential role 
for CUDC-907 in overcoming resistance to ibrutinib in 
DLBCL carrying MyD88 mutations. 
MATERIALS AND METHODS
Cell lines
The human diffuse large B-cell lymphoma 
(DLBCL)-derived cell lines SUDHL-4, SUDHL-6, 
OCI-LY-19, U-2932, NUDHL-1, OCI-LY-3, Ri-1 and 
the Hodgkin cell lines HDLM2, KMH-2 and L-428 were 
obtained from the German Collection of Microorganisms 
and Cell Cultures, Department of Human and Animal 
Cell Cultures (Braunschweig, Germany); DB, SUDHL-8, 
SUDHL-10 and the BL cell lines RAJI, RAMOS and 
CA-46 were obtained from ATCC. The DLBCL derived 
cell lines (HBL-1, TMD-8, BJAB) were provided by 
Dr. R.E. Davis (Houston, Tx). The cell lines OCI-LY-10 
was provided by Dr. E Cesarman (New York, NY) 
(Supplementary Table 4). All cell lines were grown 
to log phase at 37°C, in the presence of 5% CO2 and 
cultured in RPMI 1640 medium supplemented with 10 
to 20% heat-inactivated fetal bovine serum (Hyclone, 
GE Healthcare Life Sciences), 1% L-glutamine, and 
penicillin-streptomycin in a humid environment of 
5% CO2 at 37°C. OCI-LY-10 was cultured in Hyclone 
Iscove’s Modified Dulbecco’s Medium (GE Healthcare 
Life Sciences) with 20% heat-inactivated fetal bovine 
serum (Hyclone, GE Healthcare Life Sciences), 1% 
penicillin-streptomycin, 0.1% 2-Mercaptoethanol (GIBCO 
BRL, Gaithersburg, MD). All cell lines were authenticated 
by MSKCC Genomic Core Facility using targeted deep 
sequencing assay of 585 cancer genes (HemePACT). 
Barcoded pools were sequenced on Illumina HiSeq 
2500 to 500–1000× coverage per sample. Sequencing 
was compared to pooled normal tissue for control. We 
excluded mutations present in two databases of inherited 
variants (DBSNP and 1000 genomes) and included 
mutations found in COSMIC. Mutations absent in the 
databases of inherited variant and COSMIC but found in 
our human lymphoma database were included.
Reagents
CUDC-907 was provided by Curis (Inc., 
Massachusetts). Panobinostat and BKM-120 were 
purchased from Selleckem (Houston, TX).
In vitro proliferation assay
Cells were seeded in 96-well plates at 50,000 
cell/100 μl/well with either vehicle (DMSO 0.1%) or 
increasing concentrations of drugs for 24 to 72 hours. 
Cell viability was assessed with the non-radiactive cell 
proliferation MTS assay, using CellTiter96© Aqueous 
One Solution Reagent (Promega, Madison, WI). The 
MTS reagent was added to the culture medium at 1:5 
dilution, according to manufacturer`s instructions. 
Procedures to determine the effects of certain conditions 
on cell proliferation and apoptosis, were performed in 3 
independent experiments. The 2-tailed Student t test and 
Wilcoxon Rank test were used to estimate the statistical 
significance of differences between results from the 3 
experiments. Significance was set at P < .05. The PRISM 
software was used for the statistical analyses.
Western blotting
Cells were pelleted by centrifugation, washed once 
with ice-cold PBS, and lysed on ice for 30 min using 
the Cell Signaling lysis buffer (#9803) according to 
manufacturer`s extraction protocol. Protein quantitation 
was done using the Direct Detect system (Millipore). A 
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total of 30 μg of protein was denatured in Laemli buffer 
at 95°C for 5 minutes and western immunoblotting was 
performed using the Bio-rad system (TGX 4–15% gels). 
Transfer was performed using the Trans Blot turbo system 
(Bio-rad) into PVDF membranes. Images were acquired 
by using the Bio-rad Imaging Chemidoc MP system. 
Secondary anti-rabbit and anti-mouse HRP-conjugated 
antibodies were purchased from Bio-rad (#170-6515, 
#170-6516). Proteins were detected using the following 
antibodies purchased from Cell Signaling Technology: 
Acetyl Histone H3 Lys9 (#9649), Caspase3 (#9668), 
PARP (#9542), pPRAS40 (#13175), p4EBP1 (#2855), 
pS6 (#4856), S6 (#2217), BTK (#3533), SYK (#13198), 
MyD88 (#4283), BCL10 (#4237), IRAK4 (#4363), IkBa 
(#4812), IKKb (#2370). c-MYC (#32072) was purchased 
from Abcam. Beta-Actin was from SIGMA (A5316#).
PCR pathway arrays and qPCR
Total RNA was extracted with the Qiagen 
(Valencia, CA) RNeasy mini kit protocol. A total of 
1 μg of RNA was converted to cDNA using iScript 
cDNA synthesis kit (Bio-rad). Real-time polymerase 
chain reaction (PCR) was performed using the model 
CFX96 (Bio-rad). Primers for MyD88 and GAPDH were 
purchased from Biorad: MyD88 (qHsaCED0046947), and 
GAPDH (qHsaCED0038674).
Flow cytometry - apoptosis
To detect apoptosis, annexin V conjugated with the 
fluorescent dye fluorescein isothiocyanate (FITC) (BD 
Pharmingen, #556547) was used. In short, cells were 
stained with annexin V and propidium iodide (PI) for 
30 minutes at room temperature in dark. Cells were kept 
on ice before analysis by a flow cytometer (FACSCalibur; 
BD Biosciences).
NF-κB reporter assays 
To generate the nuclear factor kappa B (NF-kB) 
transcriptional reporters, HBL-1 and TMD-8 cell were 
first infected with a CMV Renilla luciferase lentivirus, to 
be used as internal control for normalization (QIAGEN). 
After hygromycin selection, cells were infected with a 
NF-κB reporter lentivirus, where the expression of firefly 
luciferase is under control of a synthetic minimal (m)CMV 
promoter and tandem repeats of the NF-kB transcriptional 
response element (TRE) (QIAGEN), and selected with 
puromycin. For drug experiments, cells were counted 
and seeded in fresh media at 1 × 106 cells per mL before 
treatment for the indicated times. Luciferase activity 
was measured in 96-well plates, by using the Dual-
Luciferase Reporter Assay System (Promega) according 
to manufacturer’s instruction. Readings were performed 
on a Microtiter Plate Luminometer (PerkinElmer).
Mass spectrometry studies
Cell culture, lysis and insolution digestion. 
Cells were grown as suspension cultures in RPMI 
media supplemented with 10% FBS and penicillin and 
streptomycin either unlabeled L-arginine (Arg0) and 
L-lysine (Lys0) at 50 mg/liter or equimolar amounts of 
the isotopic variants [U-13C6]-L- arginine (Arg10) and 
[U-13C6]-L–lysine HCl L-lysine (Lys6), (Cambridge 
Isotope Laboratories). After five cell doublings in 
suspension flask, cells were > 99% labeled with the 
isotopes. Cells were collected, washed with ice cold PBS 
and frozen in liquid nitrogen. Cells were thawed on ice and 
lysed in in RIPA buffer and mixed 1:1 based on protein 
quantity by micro BCA (Thermo Fisher), separated by 
SDS/PAGE, and stained with Simply Blue Stain Reagent 
(Life Technologies); and 15 gel sections excised with 
in situ trypsin digestion of polypeptides in each gel slice 
was performed as described [24]. The tryptic peptides 
were desalted by using a 2-µL bed volume of Poros 50 
R2 reversed-phase beads (Applied Biosystems) packed 
in Eppendorf gel-loading tips [25]. The purified peptides 
were diluted to 0.1% formic acid, and each gel section was 
analyzed separately by microcapillary LC with tandem MS 
by using the NanoAcquity system (Waters) with a 100-μm 
inner diameter × 10-cm length C18 column (1.7 μm 
BEH130; Waters) configured with a 180-µm × 2-cm 
trap column coupled to an OrbiElite mass spectrometer 
(Thermo Fisher Scientific). Peptides were eluted with 
a linear gradient of 0–50% acetonitrile (0.1% formic 
acid) in water (0.1% formic acid) over 200 mins with a 
flow rate of 250 nL/min.   Key parameters for the mass 
spectrometer were: automatic gain control (AGC) 3 × 106 
ions, resolution 70,000, top 10 DDA method, min signal 
1 × 105 with CID MS/MS collected in the ITMS. Tandem 
MS fragmentation spectra were searched for protein 
identification by using the Andromeda search engine 
(maxquant.org) against the reversed and concatenated 
Uniprot human protein database (downloaded from 
Uniprot Jan 24, 2014). One unique peptide was required 
for high-confidence protein identifications, and a minimum 
ratio count of two peptides (one unique and one razor) 
was required for SILAC ratio determination. Normalized 
SILAC ratios (i.e., H/L) were used for subsequent analysis. 
All MS/MS samples were analyzed by using MaxQuant 
(Max Planck Institute of Biochemistry; version 1.5.1.0) 
at default settings with a few modifications [26]. The 
default was used for first search tolerance and main search 
tolerance: 20 ppm and 6 ppm, respectively. Labels were set 
to Arg(10) and Lys(6) and enzyme specificity set as trypsin 
digestion with as many as two missed cleavages. Peptide, 
site, and protein FDR were all set to 1% with a minimum 
of one peptide needed for identification but two peptides 
needed to calculate a protein level ratio. The following 
modifications were used as variable modifications for 
identifications and included for protein quantification: 
Oncotarget14026www.impactjournals.com/oncotarget
oxidation of methionine, acetylation of the protein N 
terminus, and phosphorylation of serine, threonine, and 
tyrosine residues and carbamidomethyl modification on 
cysteine as a fixed mod. Raw data as well as original 
MaxQuant result files can be provided upon request.
Mass spectrometry data analysis 
5443 proteins were initially identified. Proteins with 
a missing value in one of the 2 cell lines or both were 
removed, as were proteins where one replicate fold change 
value was 10 times the other. 4027 proteins were then 
evaluable for the final analysis. Only proteins changing 
by at least 1.5 fold change in both forward and reverse 
experiments were considered as significantly deregulated.
ELISA
Standard ELISA was performed using the nfKb P65 
Transcription Factor Assay kit from Abcam (Cambrifge, 
MA) (#ab13312) according to manufacturer`s instructions.
Xenograft studies 
NSG mice (Jackson Laboratories) were used for 
in vivo on protocol approved by the Memorial Sloan 
Kettering Cancer Center Institutional Animal Care and 
Use Committee. Six week old female mice were injected 
subcutaneously with either 10 million TMD8 cells or 
10 million SUDHL6 cells together with matrigel. Once 
tumors reached an average volume of 100 mm3, mice 
were randomized to receive either vehicle control or 
CUDC-907 at doses of 25 mg/kg, 50 mg/kg or 100 mg/
kg p.o. daily, 5 times weekly for up to 3 weeks. Mice were 
observed daily throughout the treatment period for signs 
of morbidity/mortality. Tumors were measured three times 
per week using calipers, and volume was calculated using 
the formula: length × width2 × 0.52. Body weight was also 
assessed twice weekly. 8 hours and 24 hours after the last 
treatment, mice were sacrificed and tumors collected for 
immunoblot.
Statistical analysis
Statistical significance was determined by Student 
t test. p values < .05 were considered significant 
(*p < 0.05; **p < 0.001; ***p < 0.001; ****p < 0.0001). 
Survival was estimated with the Kaplan-Meier survival 
curve method and differences in survival were calculated 
by long-rank test (Graph Pad Prism 6.0).
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